Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Nov;30(10-11):747-752.
doi: 10.1038/s41434-023-00392-3. Epub 2023 Nov 8.

Towards affordable CRISPR genomic therapies: a task force convened by the Innovative Genomics Institute

Lea Witkowsky #  1 , Matthew Norstad #  2 , Audrey R Glynn  3 , Melinda Kliegman  4
Affiliations
Review

Towards affordable CRISPR genomic therapies: a task force convened by the Innovative Genomics Institute

Lea Witkowsky et al. Gene Ther. 2023 Nov.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Pipeline for genome therapies and traditional pharmaceuticals.
In the development of traditional pharmaceutical drugs, many compounds are eliminated from the development pipeline as companies move towards clinical trials and a commercializable product. The high failure rate of drugs in pre-clinical and early phase trials often justifies high prices upon approval because companies must recoup costs for failed drugs. Given the increase in state and federal funding of genome therapies, drug development risk has shifted from private, for-profit companies to the public.
Fig. 2
Fig. 2. Affordability Task Force design.
Experts across multiple disciplines and sectors (colored wheel slices) were divided into sub-groups (gray sections) focused on topical areas pertinent to envisioning new models to bring therapies to patients more affordably. Each sub-group was led by a member of IGI’s leadership and the project was managed by the IGI’s public impact team (white center).
See this image and copyright information in PMC

References

    1. Urnov FD. Imagine CRISPR cures. Mol Ther. 2021;29:3103–6. doi: 10.1016/j.ymthe.2021.10.019. - DOI - PMC - PubMed
    1. Henderson H. CRISPR clinical trials: a 2022 update [Internet]. Innovative Genomics Institute (IGI). https://innovativegenomics.org/news/crispr-clinical-trials-2022/. Accessed 27 Sept 2022.
    1. Court E. “Like we were being forced to gamble with our son’s life”: Health insurers won’t pay for a $2.1 million drug for kids, and parents say they’re running out of time. Business Insider [Internet]. 2019; https://www.businessinsider.com/health-insurance-companies-deny-kids-wit.... Accessed 27 Sept 2022.
    1. Tessema FA, Sarpatwari A, Rand LZ, Kesselheim AS. High-priced sickle cell gene therapies threaten to exacerbate us health disparities and establish new pricing precedents for molecular medicine. J Law Med Ethics. 2022;50:380–4. doi: 10.1017/jme.2022.66. - DOI - PubMed
    1. Murphy S, Hayward A, Troup G, Devor EJ, Coons T. Gene enrichment in an American Indian population: an excess of severe combined immunodeficiency disease. Lancet. 1980;2:502–5. doi: 10.1016/S0140-6736(80)91833-4. - DOI - PubMed

Publication types

MeSH terms